Chemical sensors based on programmable molecularly modified gold nanoparticles are tailored for the detection and discrimination between the breathprint of irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). The sensors are examined in both lab- and real-world clinical conditions. The results reveal a discriminative power accuracy of 81% between IBD and IBS and 75% between Crohn's and Colitis states.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/adhm.201600588 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!